title: [Indication and advantage of combination therapy with angiotensin II receptor blocker (ARB) and calcium channel antagonist].
abstract: Combination therapy with angiotensin II receptor blocker (ARB) and calcium channel antagonist is recommended as one of the effective therapies for hypertension. The sub-analysis of Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE) study showed that combination therapy of candesartan and amlodipine reduced the risk of major adverse cardiovascular event (MACE) by 39% (p = 0.015), as compared to that using amlodipine with non-ARB in hypertensive patients with coronary artery disease. Among the individual events in MACE, the incidence of unstable angina pectoris requiring hospitalization was significantly lower by 52% (p = 0.007). These results suggest that the combination of ARB/Ca antagonist may have an advantage not only for blood pressure lowering but also in preventing cardiovascular event in high-risk hypertensive patients.
authors: Department of Cardiology, Tokyo Women's Medical University.
authors: Junichi
authors: J
authors: Yamaguchi
authors: Hiroshi
authors: H
authors: Ogawa
authors: Nobuhisa
authors: N
authors: Hagiwara
mesh_terms: D000368:Aged; D057911:Angiotensin Receptor Antagonists / Q000008:administration & dosage*; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D003327:Coronary Disease / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male
chemical_list: D057911:Angiotensin Receptor Antagonists; D002121:Calcium Channel Blockers